Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Stent wars: Shrinkage concerns resurface in Medtronic/Boston Scientific DES trial
Medtech titan Medtronic touts a relatively minor clinical trial win for the physical integrity of its Resolute drug-eluting stent in what is otherwise a tie with Boston Scientific’s Promus Element device.
2. Legal win, buyouts boost Bard’s bottom line
C.R. Bard’s bottom 4th-quarter bottom line gets a significant boost from a nearly $900 million legal payment from rival W.L. Gore and the more than $200 million gain from selling its electrophysiology business to Boston Scientific.
1. Smith & Nephew expands sports medicine footprint with $1.7B ArthroCare buy
Smith & Nephew expands its footprint in the sport medicine market with a $1.7 billion offer for ArthoCare.
